|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 人肿瘤细胞核苷酸切除修复蛋白表达与抗癌药耐药的相关性(英文)显示文摘背景与目的:核苷酸切除修复(Nucleotideexcisionrepair,NER)是真核细胞中的DNA修复多酶系统,它可能与人肿瘤细胞对抗癌药的耐药有关。本实验将探讨NER蛋白(XPA,XPB,XPD和ERCC1)的表达与人肿瘤细胞耐药的关系。方法:采用westernblot检测美国国家癌症研究所(NationalCancerInstitute,NCI)用于抗癌药筛选的60株人肿瘤细胞的ERCC1,XPA,XPBXPD表达,并与170种抗癌药物的细胞毒试验结果进行相关性分析。结果:ERCC1,XPB和XPD的蛋白表达与抗癌药物敏感性呈负相关,在170种抗癌药物中分别有13,17和32种的耐药性与上述蛋白水平相关性显著或非常显著(P<0.05)。而XPA的表达与药物敏感性无明显正/负相关。根据已确定的6种药物作用机理分析,肿瘤细胞XPD表达与其对烷化剂类抗癌药耐药相关性显著。结论:本实验结果肿瘤细胞的XPD蛋白表达与烷化剂类抗癌药的耐药相关,提示XPD在肿瘤细胞耐药过程中起重要作用。 | 陈忠平 Areti MALAPETSA Anne MONKS Timothy G. MYERS Gérard MOHR Eaward A. SAUSVILLE Dominic A. SCUDIERO Lawrence C. PANASCI | 2002 | 癌症2002，21，3： | 12 |
| 2 | THE USE OF PLANE WAVES TO APPROXIMATE WAVE PROPAGATION IN ANISOTROPIC MEDIA显示文摘在这篇论文,我们在各向同性的媒介扩大麦克斯韦的方程的标准极端弱变化明确的表达(UWVF ) 到各向异性的媒介的盒子。我们证实内在的理论框架带在上到各向异性的媒介(然而,错误估计是还没可得到的) 并且完全描述新计划。我们然后考虑 TM 模式散布,显示出这怎么与一个各向异性的系数在二种尺寸导致一个 Helmholtz 方程并且表明怎么提出为它的 UWVF。在一种特殊情况中,集中能被证明。我们然后显示出建议的一些数字结果 UWVF 能成功地在各向异性的媒介模仿波浪繁殖。 | Tomi Huttunen Peter Monk | 2007 | Journal of Computational Mathematics2007，25，3： | 5 |
| 3 | 人肿瘤细胞ERCC2基因表达与抗癌药耐药的相关性显示文摘【目的】探讨切割修复交叉互补基因 2 (excisionrepaircross complementingrodentrepairdeficiencygene 2 ,ERCC2 )表达与人肿瘤对抗癌药耐药的关系。【方法】采用Westernblot检测美国国家癌症研究所 (NationalCancerInstitute,NCI)用于抗癌药筛选的 6 0株人肿瘤细胞的ERCC2表达 ,并与 170种抗癌药物的细胞毒试验结果进行相关性分析。【结果】肿瘤细胞ERCC2的蛋白表达水平高低不一 ,其中 6株细胞的ERCC2蛋白水平在可测定范围以下。 170种抗癌药物中有 2 8种化疗药物的耐药性与肿瘤细胞的ERCC2蛋白水平相关性显著或非常显著。根据药物作用机理分析 ,肿瘤细胞ERCC2表达与其对烷化剂和抗有丝分裂剂类抗癌药耐药相关性显著。【结论】肿瘤细胞具有DNA修复能力 ,如核苷酸切割修复 。 | 陈忠平 Anne MONKS Timothy G.MYERS Edward A.SAUSVILLE Dominic A.SCUDIERO Lawrence C.PANASCI | 2001 | 中山医科大学学报2001，22，3： | 5 |
| 4 | Predictors of Cognitive Dysfunction after Major Noncardiac Surgery显示文摘 | Terri G. Monk B Craig Weldon Cyndi W. Garvan Duane E. Dede Maria T. van der Aa Kenneth M. Heilman Joachim S. Gravenstein | 2008 | Anesthesiology2008，，1： | 5 |
| 5 | 晚期难治性卵巢上皮细胞癌在先前多次细胞毒治疗后以贝伐单抗(人工合成抗血管内皮生长因子单克隆抗体)为基础的补救治疗显示文摘Objectives.:Bevacizumab (BEV) is a humanized monoclonal antibody against vascular endothelial growth factor. We reviewed our experience with BEV in patients with recurrent advanced epithelial ovarian cancer who had failed multiple prior chemotherapeutic regimens. Methods.:Thirty-two patients not participating in an ongoing clinical trial were treated with BEV (15 mg/kg every 3 weeks IV). Demographic and clinicopathologic data,clinical outcomes,and adverse events were extracted from patient charts. RECIST and CA-125 Rustin criteria were retrospectively applied to evaluate response and progression. Median progression-free survival (PFS) and overall survival (OS) were determined using Kaplan-Meier methods. Adverse events were retrospectively categorized using the common terminology criteria for adverse events version 3. Results.:The median patient age was 57 years (range 35-80) with 84%being Caucasian and 50%having a GOG performance status of 2. FIGO stages included 80%stage III and 10%stage IV. The tumors were mostly grades 2 (29%) and 3 (64%) and serous histological subtype (69%). All patients had failed multiple prior cytotoxic chemotherapies (median of 5 (range 2-10)) prior to BEV. The median duration of follow-up was 4.8 months (range 0.4-16.3). Twenty-three patients were treated with BEV alone,2 received BEV with another chemo- therapy regimen (5-FU/lecovorin plus oxaliplatin,cyclophosphamide),and 8 initially received BEV alone,followed by BEV with capcitabine,cyclophosphamide,docetaxel,carboplatin,or weekly paclitaxel. A median of 6 cycles (range 1-20) with 196 total doses of BEV was administered. One patient was lost to follow-up after cycle 1. We observed a 16%response rate (all in those treated with BEV alone) with 62.5%of patients demonstrating stable disease. Median OS was 6.9 months,and the median PFS was 5.5 months. Three grade 3 and no grade 4 adverse events were observed. Grade 3 toxicities included hypertension,proteinuria,and enterocutaneous fistula. The fistula occurred after 5 cycles of BEV in a patient who had undergone 7 debulking surgeries prior to BEV. Conclusions.:BEV is generally well tolerated after multiple prior cytotoxic regimens and results in significant clinical benefit among women with recurrent ovarian cancer. | Monk B.J. Josephs-Cowan C.A. 马超 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，12： | 2 |
| 6 | Postoperative cognitive dysfunction in middle-aged patients 显示文摘 | Johnson T Monk T Rasmussen LS | 2002 | Anesthesiology2002，96，6： | 2 |
| 7 | Predictors of Cognitive Dysfunction after Major Noncardiac Surgery显示文摘 | Terri G. Monk B Craig Weldon Cyndi W. Garvan Duane E. Dede Maria T. van der Aa Kenneth M. Heilman Joachim S. Gravenstein | 2008 | Anesthesiology2008，，1： | 2 |
| 8 | The Impact of a Statewide Pre-Hospital STEMI Strategy to Bypass Hospitals Without Percutaneous Coronary Intervention Capability on Treatment Times显示文摘 | Emil L. Fosbol Christopher B. Granger James G. Jollis Lisa Monk Li Lin Barbara L. Lytle Ying Xian J. Lee Garvey Greg Mears Claire C. Corbett Eric D. Peterson Seth W. Glickman | 2013 | Circulation2013，，5： | 2 |
| 9 | The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research显示文摘 | Buysse DJ Reynolds CF Monk TH | 1989 | Psychiatry Res1989，28，2： | 1 |
| 10 | Cladistic analysis of a problematic ammonite group : the Hamitidae ( Creataceous, Albian-Turonian) and proposals for new cladistic terms 显示文摘 | Monks N | 2002 | Palaeontology2002，45，： | 1 |
| 11 | STRO-1,HOP-26 (CD63),CD49a and SB-10(CD166) as markers of primitive human marrow stromal cells and their differentiated progeny: a comparative investigation in vitro 显示文摘 | Stewart K Monk P Walsh S | 2003 | Cell Tissue Res2003，313，3： | 1 |
| 12 | Answers:A model for watershed planning 显示文摘 | Beasley D B Huggins L F Monke E J | 1981 | Transaction of the ASCE1981，23，4： | 1 |
| 13 | Pittsburgh sleep quality index:A new instrument for psychiatric practice and research显示文摘 | Buysse DJ Reynolds CF Monk TH | 1989 | Psychiatry Res1989，28，： | 1 |
| 14 | Zinc hydroxystannate as an alternative synergist to antimony trioxide in polyester resins containing halogenated flame retardants 显示文摘 | Cusack P A Heer M S Monk A W | 1997 | Polymer Degradation and Stability1997，58，2： | 1 |
| 15 | A Developmental Examination of Gender Differences in Brain En- gagement During Evaluation of Threat 显示文摘 | MCCLURE E B MONK C S NELSON E E | 2004 | Biological Psychiatry2004，，55： | 1 |
| 16 | Enhanced stress reactivity in paediatric anxiety disorders: implications for future cardiovascular health显示文摘 | Monk C Kovelenko P Ellman LM | 2001 | Int J Neuropsychopharmacol2001，4，2： | 1 |
| 17 | Practice guidelines for medical nutrition therapy provided by dietitians for persons with non-insulin dependent diabetes mellitus 显示文摘 | MONK A BARRY B MCCLAIN K | 1995 | J Am Diet Assoc1995，95，： | 1 |
| 18 | HPV infection and number of lifetime sexual partners are strong predictors for'natural'regression of CIN2and3显示文摘 | Chan JK Monk BJ Brewer C | 2003 | Br J Cancer2003，89，6： | 1 |
| 19 | The NCI anti-cancer drug screem a smart screen to identify effec- tors of novel targets显示文摘 | MONKS A SCUDIERO D A JOHNSON G S | 1997 | Anti-Cancer Drug Des1997，12，： | 1 |
| 20 | The Pittsburgh Sleep Quality Index: a new instrument for psychiatric prac- tice and research 显示文摘 | Buysse DJ Reynolds CF 3rd Monk TH eta/ | 1989 | Psych Res1989，28，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员